XML 22 R6.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents ($328 and $333 related to VIEs) $ 2,135 $ 2,829
Marketable securities 59 130
Accounts receivable, net ($142 and $92 related to VIEs) 1,073 921
Contract assets ($17 and $130 related to VIEs) 1,146 1,138
Investment in NuScale(1) [1] 1,579 0
Other current assets ($26 and $32 related to VIEs) 450 157
Total current assets 6,442 5,175
Noncurrent assets    
PP&E, net ($41 and $46 related to VIEs) 464 494
Investments 543 2,828
Other assets ($17 related to VIEs for both periods) 787 646
Total noncurrent assets 1,794 3,968
Total assets 8,236 9,143
Current liabilities    
Accounts payable ($205 and $233 related to VIEs) 1,482 1,220
Contract liabilities ($254 and $278 related to VIEs) 633 684
Accrued salaries, wages and benefits ($9 and $18 related to VIEs) 621 640
Other accrued liabilities ($31 and $37 related to VIEs) 642 527
Total current liabilities 3,378 3,071
Long-term debt 1,070 1,104
Deferred taxes 6 468
Other noncurrent liabilities ($3 related to VIEs for both periods) 505 508
Contingencies and commitments
Shareholders' equity    
Common stock — authorized 375,000,000 shares ($0.01 par value); issued and outstanding — 152,047,739 and 169,228,759 shares in 2025 and 2024, respectively 2 2
APIC 443 1,174
AOCI (265) (351)
Retained earnings 3,064 3,124
Total shareholders' equity 3,244 3,949
NCI 33 43
Total equity 3,277 3,992
Total liabilities and equity $ 8,236 $ 9,143
[1]
(1) Our investment in NuScale was included in Investments as of December 31, 2024.